Fig. 7: mGluR4 suppresses the anti-tumor efficacy of the DC-based tumor vaccine.

A The schematic of the preparation of DC-based tumor vaccine. B Diagram of the therapeutic schedule of DC-based tumor vaccine in Hepa1-6BL tumor-bearing mice. Mice were sacrificed on day 21 and livers were collected for tumor burden quantification (C, D) or flow cytometry analysis (E–H). C Weights of livers, representative images of livers, and the number of liver tumor nodules with different sizes (n = 8 mice per group). D ALT and AST levels in serum of tumor-bearing mice from (C) on day 21 (n = 6 mice per group). E The number of CD4⁺, CD8⁺ T, and NK cells among CD45.2⁺ cells in Hepa1-6BL orthotopic liver tumors (n = 5 mice per group). F The number of granzyme B and IFNγ expressing lymphocytes amongst their corresponding subsets after the tumor single cell suspension was stimulated with PMA/ionomycin plus protein transporter inhibitor for 6 h (n = 5 mice per group). G Frequency of CD4⁺ T, CD8⁺ T, and NK cells in the inguinal LN of Hepa1-6BL tumor-bearing mice (n = 5 mice per group). H The frequency of tumor-associated macrophages (TAM) and tumor-infiltrating DCs and neutrophil cells in Hepa1-6BL tumors (n = 5 mice per group). I Weights and the number of liver tumor with different sizes. Mice were intravenously injected with Hepa1-6BL tumor cell lysate-loaded WT BMDCs (3 × 10⁶) pretreated with forskolin (10 μM, 24 h) on days 3, 9 and 15 relatives to Hepa1-6BL tumor cell inoculation (n = 5 mice per group). Data were presented as mean ± SEM. Statistical significance was determined by unpaired t-test two-tailed (C–I). All biological experiments were repeated at least three times and yielded consistent results. Source data are provided as a Source Data file.